Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Thirteen new option listings and four option delistings on May 28th » 08:30
05/28/20
05/28
08:30
05/28/20
08:30
CFRX

ContraFect

$5.35 /

-0.045 (-0.83%)

, FREQ

Frequency Therapeutics

$18.27 /

+0.8 (+4.58%)

, HARP

Harpoon Therapeutics

$21.77 /

-3.23 (-12.92%)

, HOOK

Hookipa Pharma

$11.23 /

+0.73 (+6.95%)

, HSTO

Histogen

$4.61 /

+4.054 (+729.14%)

, IFRX

InflaRx

$8.36 /

+0.2 (+2.45%)

, KNSA

Kiniksa

$20.86 /

-0.89 (-4.09%)

, KZR

Kezar Life Sciences

$5.30 /

+0.05 (+0.95%)

, LQDA

Liquidia Technologies

$9.03 /

+0.05 (+0.56%)

, OVID

Ovid Therapeutics

$5.71 /

-0.97 (-14.52%)

, PRVL

Prevail Therapeutics

$16.83 /

-0.38 (-2.21%)

, CNAT

Conatus

$0.00 /

+ (+0.00%)

, CORV

Correvio

$0.42 /

+ (+0.00%)

, CTRC

Centric Brands

$0.19 /

-0.0279 (-12.65%)

, UNT

Unit Corp.

/

+

New option listings for…

New option listings for May 28th include ContraFect (CFRX), Centric Brands Inc (CTRCQ), Frequency Therapeutics Inc (FREQ), Harpoon Therapeutics Inc (HARP), HOOKIPA Pharma Inc (HOOK), Histogen Inc (HSTO), InflaRx NV (IFRX), Kiniksa Pharmaceuticals Ltd (Class A Stock) (KNSA), Kezar Life Sciences Inc (KZR), Liquidia Technologies Inc (LQDA), Ovid Therapeutics (OVID), Prevail Therapeutics Inc (PRVL), and Unit Corp (UNTCQ). Option delistings effective May 28th include Conatus Pharmaceuticals Inc (CNAT), Correvio Pharma Corporation (CORV), Centric Brands Inc (CTRC), and Unit Corp (UNT).

ShowHide Related Items >><<
UNT Unit Corp.
/

+

PRVL Prevail Therapeutics
$16.83 /

-0.38 (-2.21%)

OVID Ovid Therapeutics
$5.71 /

-0.97 (-14.52%)

LQDA Liquidia Technologies
$9.03 /

+0.05 (+0.56%)

KZR Kezar Life Sciences
$5.30 /

+0.05 (+0.95%)

KNSA Kiniksa
$20.86 /

-0.89 (-4.09%)

IFRX InflaRx
$8.36 /

+0.2 (+2.45%)

HSTO Histogen
$4.61 /

+4.054 (+729.14%)

HOOK Hookipa Pharma
$11.23 /

+0.73 (+6.95%)

HARP Harpoon Therapeutics
$21.77 /

-3.23 (-12.92%)

FREQ Frequency Therapeutics
$18.27 /

+0.8 (+4.58%)

CTRC Centric Brands
$0.19 /

-0.0279 (-12.65%)

CORV Correvio
$0.42 /

+ (+0.00%)

CNAT Conatus
$0.00 /

+ (+0.00%)

CFRX ContraFect
$5.35 /

-0.045 (-0.83%)

CFRX ContraFect
$5.35 /

-0.045 (-0.83%)

10/02/19 Piper Sandler
Piper says design differentiates ContraFect trial from other antibiotic studies
06/11/19 Maxim
ContraFect initiated with a Buy at Maxim
FREQ Frequency Therapeutics
$18.27 /

+0.8 (+4.58%)

05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
HARP Harpoon Therapeutics
$21.77 /

-3.23 (-12.92%)

05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
04/16/20 Citi
Citi opens 'positive 90-day catalyst watch' on Harpoon Therapeutics
02/28/20
Fly Intel: Top five analyst initiations
02/27/20 SunTrust
Harpoon Therapeutics initiated with a Buy at SunTrust
HOOK Hookipa Pharma
$11.23 /

+0.73 (+6.95%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
HSTO Histogen
$4.61 /

+4.054 (+729.14%)

IFRX InflaRx
$8.36 /

+0.2 (+2.45%)

05/21/20 BMO Capital
InflaRx price target raised to $7 from $4 at BMO Capital
05/21/20 Raymond James
Raymond James doubles InflaRx price target to $20 ahead of COVID data
05/21/20 Raymond James
InflaRx price target raised to $20 from $10 at Raymond James
04/30/20 Raymond James
InflaRx upgraded to Outperform from Market Perform at Raymond James
KNSA Kiniksa
$20.86 /

-0.89 (-4.09%)

04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
12/06/19 Goldman Sachs
Kiniksa assumed to Buy from Neutral at Goldman Sachs
08/14/19 JMP Securities
Kiniksa price target lowered to $35 from $44 at JMP Securities
KZR Kezar Life Sciences
$5.30 /

+0.05 (+0.95%)

05/05/20 H.C. Wainwright
Kezar Life Sciences price target lowered to $9 from $15 at H.C. Wainwright
07/29/19 H.C. Wainwright
Kezar Life Sciences initiated with a Buy at H.C. Wainwright
LQDA Liquidia Technologies
$9.03 /

+0.05 (+0.56%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
OVID Ovid Therapeutics
$5.71 /

-0.97 (-14.52%)

05/22/20 Cantor Fitzgerald
Zynerba price target raised to $21 from $12 at Cantor Fitzgerald
05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
03/30/20 Piper Sandler
Piper says Ovid data suggests potential use for soticlestat in CDD/Dup15q
09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
PRVL Prevail Therapeutics
$16.83 /

-0.38 (-2.21%)

05/14/20 Piper Sandler
Prevail's 'quiet' Q1 report 'a victory in this environment,' says Piper Sandler
04/27/20 Piper Sandler
Prevail 20% pullback brings 'unique' buying opportunity, says Piper Sandler
04/09/20
Fly Intel: Top five analyst initiations
04/09/20 Piper Sandler
Prevail Therapeutics initiated with an Overweight at Piper Sandler
CNAT Conatus
$0.00 /

+ (+0.00%)

CORV Correvio
$0.42 /

+ (+0.00%)

12/11/19 H.C. Wainwright
Correvio downgraded to Neutral from Buy at H.C. Wainwright
09/03/19 Cantor Fitzgerald
Correvio initiated with an Overweight at Cantor Fitzgerald
CTRC Centric Brands
$0.19 /

-0.0279 (-12.65%)

UNT Unit Corp.
/

+

03/20/20 Stephens
Stephens upgrades Hess, downgrades 11 others in E&P following oil's melt down
03/20/20 Stephens
Unit Corp. downgraded to Underweight from Equal Weight at Stephens
01/06/20 Raymond James
Unit Corp. downgraded at Raymond James on commodity price weakness
01/06/20 Raymond James
Unit Corp. downgraded to Underperform from Market Perform at Raymond James
UNT Unit Corp.
/

+

PRVL Prevail Therapeutics
$16.83 /

-0.38 (-2.21%)

OVID Ovid Therapeutics
$5.71 /

-0.97 (-14.52%)

LQDA Liquidia Technologies
$9.03 /

+0.05 (+0.56%)

KZR Kezar Life Sciences
$5.30 /

+0.05 (+0.95%)

KNSA Kiniksa
$20.86 /

-0.89 (-4.09%)

IFRX InflaRx
$8.36 /

+0.2 (+2.45%)

HOOK Hookipa Pharma
$11.23 /

+0.73 (+6.95%)

HARP Harpoon Therapeutics
$21.77 /

-3.23 (-12.92%)

FREQ Frequency Therapeutics
$18.27 /

+0.8 (+4.58%)

CFRX ContraFect
$5.35 /

-0.045 (-0.83%)

CORV Correvio
$0.42 /

+ (+0.00%)

LQDA Liquidia Technologies
$9.03 /

+0.05 (+0.56%)

KZR Kezar Life Sciences
$5.30 /

+0.05 (+0.95%)

KNSA Kiniksa
$20.86 /

-0.89 (-4.09%)

IFRX InflaRx
$8.36 /

+0.2 (+2.45%)

HARP Harpoon Therapeutics
$21.77 /

-3.23 (-12.92%)

CTRC Centric Brands
$0.19 /

-0.0279 (-12.65%)

CFRX ContraFect
$5.35 /

-0.045 (-0.83%)

CORV Correvio
$0.42 /

+ (+0.00%)

Over a week ago
Syndicate
Kiniksa files to sell 1.6M shares of common stock for holders  17:20
05/21/20
05/21
17:20
05/21/20
17:20
KNSA

Kiniksa

$21.56 /

+0.01 (+0.05%)

 
ShowHide Related Items >><<
KNSA Kiniksa
$21.56 /

+0.01 (+0.05%)

KNSA Kiniksa
$21.56 /

+0.01 (+0.05%)

04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
12/06/19 Goldman Sachs
Kiniksa assumed to Buy from Neutral at Goldman Sachs
08/14/19 JMP Securities
Kiniksa price target lowered to $35 from $44 at JMP Securities
KNSA Kiniksa
$21.56 /

+0.01 (+0.05%)

KNSA Kiniksa
$21.56 /

+0.01 (+0.05%)

Syndicate
Kiniksa 2.4M share Spot Secondary priced at $18.25 » 06:11
05/14/20
05/14
06:11
05/14/20
06:11
KNSA

Kiniksa

$18.97 /

-2.13 (-10.09%)

The deal range was…

The deal range was $17.25-$18.25 and the size was increased to 2.4M shares from 1.8M shares. Goldman Sachs, JPMorgan and BofA acted as joint book running managers for the offering.

ShowHide Related Items >><<
KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
12/06/19 Goldman Sachs
Kiniksa assumed to Buy from Neutral at Goldman Sachs
08/14/19 JMP Securities
Kiniksa price target lowered to $35 from $44 at JMP Securities
KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

  • 14
    May
KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

On The Fly
Fly Intel: After-Hours Movers » 19:04
05/13/20
05/13
19:04
05/13/20
19:04
KNSA

Kiniksa

$18.97 /

-2.13 (-10.09%)

, ARVN

Arvinas

$51.00 /

-4.4 (-7.94%)

, SDC

SmileDirectClub

$7.70 /

-0.39 (-4.82%)

, JACK

Jack in the Box

$63.59 /

-2.29 (-3.48%)

, VRTU

Virtusa

$31.75 /

-1.95 (-5.79%)

, ONEM

1Life Healthcare

$26.78 /

-0.44 (-1.62%)

, PANL

Pangaea Logistics

$2.30 /

-0.03 (-1.29%)

, FCAU

Fiat Chrysler

$7.90 /

-0.27 (-3.30%)

, MA

MasterCard

$269.58 /

-2.66 (-0.98%)

, IMGN

ImmunoGen

$4.09 /

-0.19 (-4.44%)

, ALLO

Allogene Therapeutics

$30.99 /

-1.56 (-4.79%)

, IMUX

Immunic

$10.00 /

-0.72 (-6.72%)

, OII

Oceaneering

$4.64 /

-0.26 (-5.31%)

, FLO

Flowers Foods

$22.64 /

+0.17 (+0.76%)

, CSCO

Cisco

$41.91 /

-1.28 (-2.96%)

, RVLV

Revolve Group

$14.92 /

+0.49 (+3.40%)

, BRP

BRP Group

$8.99 /

-1.01 (-10.10%)

, JAKK

JAKKS Pacific

$0.59 /

-0.0939 (-13.81%)

, RKDA

Arcadia Biosciences

$4.88 /

+0.15 (+3.17%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VRTU Virtusa
$31.75 /

-1.95 (-5.79%)

SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

RVLV Revolve Group
$14.92 /

+0.49 (+3.40%)

RKDA Arcadia Biosciences
$4.88 /

+0.15 (+3.17%)

ONEM 1Life Healthcare
$26.78 /

-0.44 (-1.62%)

OII Oceaneering
$4.64 /

-0.26 (-5.31%)

MA MasterCard
$269.58 /

-2.66 (-0.98%)

KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

JAKK JAKKS Pacific
$0.59 /

-0.0939 (-13.81%)

JACK Jack in the Box
$63.59 /

-2.29 (-3.48%)

IMUX Immunic
$10.00 /

-0.72 (-6.72%)

IMGN ImmunoGen
$4.09 /

-0.19 (-4.44%)

FLO Flowers Foods
$22.64 /

+0.17 (+0.76%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

BRP BRP Group
$8.99 /

-1.01 (-10.10%)

ARVN Arvinas
$51.00 /

-4.4 (-7.94%)

ALLO Allogene Therapeutics
$30.99 /

-1.56 (-4.79%)

KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
12/06/19 Goldman Sachs
Kiniksa assumed to Buy from Neutral at Goldman Sachs
08/14/19 JMP Securities
Kiniksa price target lowered to $35 from $44 at JMP Securities
ARVN Arvinas
$51.00 /

-4.4 (-7.94%)

05/13/20 Piper Sandler
Arvinas pullback represents a buying opportunity, says Piper Sandler
05/13/20 Wedbush
Arvinas removed from Best Ideas List at Wedbush
05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Oppenheimer
Arvinas initiated with a Perform at Oppenheimer
SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

04/07/20 Goldman Sachs
SmileDirectClub downgraded to Sell from Neutral at Goldman Sachs
04/06/20 Guggenheim
SmileDirectClub removed from Best Ideas list at Guggenheim
03/02/20
Fly Intel: Top five analyst downgrades
03/02/20 UBS
SmileDirectClub downgraded to Neutral from Buy at UBS
JACK Jack in the Box
$63.59 /

-2.29 (-3.48%)

05/11/20 SunTrust
Jack in the Box price target raised to $79 from $66 at SunTrust
04/16/20 SunTrust
Jack in the Box price target raised to $66 from $49 at SunTrust
04/16/20 Wells Fargo
Jack in the Box price target lowered to $72 from $105 at Wells Fargo
04/16/20 Oppenheimer
Jack in the Box price target lowered to $70 from $96 at Oppenheimer
VRTU Virtusa
$31.75 /

-1.95 (-5.79%)

02/07/20 Needham
Virtusa price target raised to $56 from $48 at Needham
01/07/20 Barrington
Adtalem, Tivity, Virtusa among Barrington's Best Ideas for 2020
01/06/20 Wedbush
Wedbush says buy Virtusa on weakness as market 'overreacts' to Citi renewal
01/06/20 Wedbush
Virtusa pullback on Citi renewal news a buying opportunity, says Wedbush
ONEM 1Life Healthcare
$26.78 /

-0.44 (-1.62%)

02/25/20 Morgan Stanley
1Life Healthcare initiated with an Overweight at Morgan Stanley
02/25/20 JPMorgan
1Life Healthcare initiated with an Overweight at JPMorgan
02/25/20 SunTrust
1Life Healthcare initiated with a Buy at SunTrust
02/25/20 Citi
1Life Healthcare initiated with a Neutral at Citi
PANL Pangaea Logistics
$2.30 /

-0.03 (-1.29%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

03/24/20 UBS
Tesla and BMW upgraded, Ford downgraded at UBS
03/11/20 Morgan Stanley
Morgan Stanley cuts estimates for GM, Ford and FCA on coronavirus 'demand shock'
12/18/19 Evercore ISI
Evercore ISI upgrades Fiat Chrysler to Outperform after Peugeot deal formalized
12/18/19 Evercore ISI
Fiat Chrysler upgraded to Outperform from In Line at Evercore ISI
MA MasterCard
$269.58 /

-2.66 (-0.98%)

05/06/20 Stephens
Visa franchises will exit recession stronger, says Stephens
05/06/20 Stephens
MasterCard price target raised to $304 from $286 at Stephens
05/04/20 BMO Capital
Visa price target lowered to $213 from $234 at BMO Capital
04/30/20 RBC Capital
MasterCard price target raised to $308 from $287 at RBC Capital
IMGN ImmunoGen
$4.09 /

-0.19 (-4.44%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
05/15/19 H.C. Wainwright
H.C. Wainwright says 'wrong again' about ImmunoGen, lowers price target to $4
ALLO Allogene Therapeutics
$30.99 /

-1.56 (-4.79%)

05/13/20 H.C. Wainwright
Allogene's TurboCARs shows promise for solid tumors, says H.C. Wainwright
04/13/20
Fly Intel: Top five analyst initiations
04/13/20 SunTrust
Allogene Therapeutics initiated with a Buy at SunTrust
04/13/20 SunTrust
Allogene Therapeutics initiated with a Buy at SunTrust
IMUX Immunic
$10.00 /

-0.72 (-6.72%)

05/11/20
Fly Intel: Top five analyst initiations
05/11/20 H.C. Wainwright
Immunic initiated with a Buy, $45 price target at H.C. Wainwright
03/25/20
Fly Intel: Top five analyst initiations
03/25/20 Roth Capital
Immunic initiated with a Buy at Roth Capital
OII Oceaneering
$4.64 /

-0.26 (-5.31%)

04/24/20 Citi
Oceaneering upgraded to Buy from Neutral at Citi
04/05/20 Bernstein
Oceaneering upgraded to Market Perform from Underperform at Bernstein
03/19/20 Wolfe Research
Oceaneering downgraded to Peer Perform from Outperform at Wolfe Research
03/13/20 Wells Fargo
Drillers downgraded at Wells Fargo on recent sell off in commodity prices
FLO Flowers Foods
$22.64 /

+0.17 (+0.76%)

01/22/20 Jefferies
Flowers Foods initiated with a Hold at Jefferies
01/22/20 Jefferies
Flowers Foods initiated with a Hold at Jefferies
12/11/19 Deutsche Bank
Flowers Foods resumed with a Hold at Deutsche Bank
12/11/19 Deutsche Bank
Flowers Foods resumed with a Hold at Deutsche Bank
CSCO Cisco
$41.91 /

-1.28 (-2.96%)

04/17/20 KeyBanc
Cisco downgraded to Sector Weight from Overweight at KeyBanc
04/16/20 Cleveland Research
Cisco dips after Cleveland Research calls out partners' worsening trends
04/14/20 MKM Partners
Cisco price target lowered to $40 from $48 at MKM Partners
04/06/20 Raymond James
Cisco price target lowered to $48 from $54 at Raymond James
RVLV Revolve Group
$14.92 /

+0.49 (+3.40%)

03/19/20
Fly Intel: Top five analyst downgrades
03/19/20 Jefferies
Jefferies cuts Revolve Group to Hold, lowers price target to $9
03/19/20 Jefferies
Revolve Group downgraded to Hold from Buy at Jefferies
03/18/20 Nomura Instinet
Revolve Group initiated with a Neutral at Nomura Instinet
BRP BRP Group
$8.99 /

-1.01 (-10.10%)

03/26/20 Keefe Bruyette
BRP Group price target lowered to $16 from $22 at Keefe Bruyette
02/21/20 Northcoast
BRP Group downgraded to Neutral from Buy at Northcoast
11/18/19
Fly Intel: Top five analyst initiations
11/18/19 Jefferies
BRP Group initiated with a Hold at Jefferies
JAKK JAKKS Pacific
$0.59 /

-0.0939 (-13.81%)

12/13/19 Jefferies
Removal, delay of China tariffs give 'reprieve' to toy companies, says Jefferies
RKDA Arcadia Biosciences
$4.88 /

+0.15 (+3.17%)

06/06/19 H.C. Wainwright
Arcadia Biosciences price target lowered to $14 from $20 at H.C. Wainwright
VRTU Virtusa
$31.75 /

-1.95 (-5.79%)

SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

RVLV Revolve Group
$14.92 /

+0.49 (+3.40%)

RKDA Arcadia Biosciences
$4.88 /

+0.15 (+3.17%)

PANL Pangaea Logistics
$2.30 /

-0.03 (-1.29%)

ONEM 1Life Healthcare
$26.78 /

-0.44 (-1.62%)

OII Oceaneering
$4.64 /

-0.26 (-5.31%)

MA MasterCard
$269.58 /

-2.66 (-0.98%)

KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

JAKK JAKKS Pacific
$0.59 /

-0.0939 (-13.81%)

JACK Jack in the Box
$63.59 /

-2.29 (-3.48%)

IMUX Immunic
$10.00 /

-0.72 (-6.72%)

IMGN ImmunoGen
$4.09 /

-0.19 (-4.44%)

FLO Flowers Foods
$22.64 /

+0.17 (+0.76%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

BRP BRP Group
$8.99 /

-1.01 (-10.10%)

ARVN Arvinas
$51.00 /

-4.4 (-7.94%)

ALLO Allogene Therapeutics
$30.99 /

-1.56 (-4.79%)

  • 14
    May
SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

MA MasterCard
$269.58 /

-2.66 (-0.98%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

ONEM 1Life Healthcare
$26.78 /

-0.44 (-1.62%)

OII Oceaneering
$4.64 /

-0.26 (-5.31%)

MA MasterCard
$269.58 /

-2.66 (-0.98%)

KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

JAKK JAKKS Pacific
$0.59 /

-0.0939 (-13.81%)

JACK Jack in the Box
$63.59 /

-2.29 (-3.48%)

IMUX Immunic
$10.00 /

-0.72 (-6.72%)

IMGN ImmunoGen
$4.09 /

-0.19 (-4.44%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

ARVN Arvinas
$51.00 /

-4.4 (-7.94%)

ALLO Allogene Therapeutics
$30.99 /

-1.56 (-4.79%)

SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

RVLV Revolve Group
$14.92 /

+0.49 (+3.40%)

ONEM 1Life Healthcare
$26.78 /

-0.44 (-1.62%)

MA MasterCard
$269.58 /

-2.66 (-0.98%)

JACK Jack in the Box
$63.59 /

-2.29 (-3.48%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

Syndicate
Kiniksa files to sell 1.8M shares of Class A common stock » 17:13
05/13/20
05/13
17:13
05/13/20
17:13
KNSA

Kiniksa

$18.97 /

-2.13 (-10.09%)

Goldman Sachs & Co.,…

Goldman Sachs & Co., J.P. Morgan Securities, and BofA Securities are acting as joint book-running managers for the offering. Wedbush Securities and JMP Securities are acting as co-managers for the offering.

ShowHide Related Items >><<
KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
12/06/19 Goldman Sachs
Kiniksa assumed to Buy from Neutral at Goldman Sachs
08/14/19 JMP Securities
Kiniksa price target lowered to $35 from $44 at JMP Securities
KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

Hot Stocks
Kiniksa reports vixarelimab data in diseases characterized by chronic pruritus » 08:05
05/11/20
05/11
08:05
05/11/20
08:05
KNSA

Kiniksa

$20.43 /

+0.03 (+0.15%)

The exploratory Phase 2…

The exploratory Phase 2 trial in diseases characterized by chronic pruritus enrolled patients experiencing moderate-to-severe pruritus and assigned them to one of the following cohorts based upon their diagnosis: plaque psoriasis, chronic idiopathic pruritus, lichen simplex chronicus, chronic idiopathic urticaria, or lichen planus. Each cohort was evaluated as an independently randomized sub-study. Patients received a loading dose of vixarelimab 720 mg or placebo subcutaneously followed by vixarelimab 360 mg or placebo SC weekly for 8 weeks. The primary efficacy endpoint was percent change from baseline in weekly-average WI-NRS at Week 8. The plaque psoriasis cohort achieved a statistically significant reduction in weekly-average WI-NRS at Week 8. Least squares-mean change from baseline in weekly-average WI-NRS at Week 8 was -66.5% in vixarelimab recipients compared to -29.0% in placebo recipients. In the chronic idiopathic pruritus cohort, the LS-mean change from baseline in weekly-average WI-NRS at Week 8 was -52.4% in vixarelimab recipients compared to -48.8% in placebo recipients. The lichen simplex chronicus, chronic idiopathic urticaria and lichen planus cohorts showed encouraging efficacy results as measured by percent change from baseline in weekly-average WI-NRS at Week 8. Comparative summary statistics were not performed due to the small number of patients enrolled in each cohort. Vixarelimab was well-tolerated, and no dose-limiting adverse events were recorded. Kiniksa is conducting additional responder and biomarker analyses across indications to help determine next steps, including a potential dose-ranging Phase 2b trial. The data presentations from the open-label treatment protocol of mavrilimumab in COVID-19 pneumonia and hyperinflammation and the exploratory Phase 2 trial of vixarelimab in diseases characterized by chronic pruritus are available through the Investors and Media section of Kiniksa's website.

ShowHide Related Items >><<
KNSA Kiniksa
$20.43 /

+0.03 (+0.15%)

04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
12/06/19 Goldman Sachs
Kiniksa assumed to Buy from Neutral at Goldman Sachs
08/14/19 JMP Securities
Kiniksa price target lowered to $35 from $44 at JMP Securities
Hot Stocks
Kiniksa reports data for mavrilimumab in COVID-19 pneumonia » 08:03
05/11/20
05/11
08:03
05/11/20
08:03
KNSA

Kiniksa

$20.43 /

+0.03 (+0.15%)

Kiniksa Pharmaceuticals…

Kiniksa Pharmaceuticals provided additional data from the open-label treatment protocol with mavrilimumab, an investigational fully-human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha, in patients with severe coronavirus 2019 pneumonia and hyperinflammation. The company also provided data from the exploratory Phase 2 trial for vixarelimab, an investigational fully-human monoclonal antibody that targets oncostatin M receptor beta, in diseases characterized by chronic pruritus. The mavrilimumab open-label treatment protocol was a prospective, interventional, single-active-arm, single-center pilot experience in Italy. Thirteen non-mechanically ventilated patients with severe COVID-19 pneumonia and hyperinflammation were treated with a single intravenous dose of mavrilimumab upon admission to the hospital. Twenty-six contemporaneous non-mechanically ventilated patients with severe COVID-19 pneumonia and hyperinflammation and with similar characteristics upon admission to the hospital, including comorbidities, baseline inflammatory markers and respiratory dysfunction, were evaluated as a control group. All patients in the treatment protocol received optimum local standard of care, including protease inhibitors and antiviral therapies. Over the course of the 14-day follow-up period, mavrilimumab-treated patients experienced greater and earlier clinical improvements than control-group patients, including earlier weaning from supplemental oxygen, shorter hospitalizations, and no deaths. At day 14 of the follow-up period, 85% of mavrilimumab-treated patients and 42% of control-group patients had attained the clinical improvement endpoint. Mavrilimumab-treated patients reached the clinical improvement endpoint earlier compared to control-group patients. During the 14-day follow-up period, there was a 0% incidence of death in mavrilimumab-treated patients compared to 27% in control-group patients. Eight percent of mavrilimumab-treated patients received mechanical ventilation, compared to 35% of control-group patients. Mavrilimumab-treated patients were discharged from the hospital earlier than control-group patients. Mavrilimumab was well-tolerated in all patients, without infusion reactions. P-values above are unadjusted for multiplicity. Kiniksa is engaged with the U.S. Food and Drug Administration and is preparing for a potential registrational development program for mavrilimumab in COVID-19 pneumonia and hyperinflammation. In parallel, academic investigators in the U.S. and Italy are planning investigator-initiated placebo-controlled studies.

ShowHide Related Items >><<
KNSA Kiniksa
$20.43 /

+0.03 (+0.15%)

04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
12/06/19 Goldman Sachs
Kiniksa assumed to Buy from Neutral at Goldman Sachs
08/14/19 JMP Securities
Kiniksa price target lowered to $35 from $44 at JMP Securities
Over a month ago
Hot Stocks
Kiniksa expects data from Phase 1 trial of KPL-404 in 2H20 » 07:40
04/28/20
04/28
07:40
04/28/20
07:40
KNSA

Kiniksa

$21.00 /

+1.18 (+5.95%)

Kiniksa is conducting a…

Kiniksa is conducting a single-ascending-dose Phase 1 clinical trial of KPL-404 in healthy volunteers. The first-in-human trial will provide safety data and pharmacokinetics as well as receptor occupancy and T-cell Dependent Antibody Response. The company continues to expect data in the second half of 2020.

ShowHide Related Items >><<
KNSA Kiniksa
$21.00 /

+1.18 (+5.95%)

04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
12/06/19 Goldman Sachs
Kiniksa assumed to Buy from Neutral at Goldman Sachs
08/14/19 JMP Securities
Kiniksa price target lowered to $35 from $44 at JMP Securities
Hot Stocks
Kiniksa continues to expect data from Phase 2 trial of vixarelimab in 1H20 » 07:40
04/28/20
04/28
07:40
04/28/20
07:40
KNSA

Kiniksa

$21.00 /

+1.18 (+5.95%)

Kiniksa continues to…

Kiniksa continues to expect data from cohorts of an exploratory Phase 2 trial of vixarelimab in diseases characterized by chronic pruritus in the first half of 2020.

ShowHide Related Items >><<
KNSA Kiniksa
$21.00 /

+1.18 (+5.95%)

04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
12/06/19 Goldman Sachs
Kiniksa assumed to Buy from Neutral at Goldman Sachs
08/14/19 JMP Securities
Kiniksa price target lowered to $35 from $44 at JMP Securities
Hot Stocks
Kiniksa, Kite expect to commence Phase 2 trial in 2H20 » 07:39
04/28/20
04/28
07:39
04/28/20
07:39
KNSA

Kiniksa

$21.00 /

+1.18 (+5.95%)

, GILD

Gilead

$79.90 /

+0.24 (+0.30%)

Kiniksa (KNSA) and Kite,…

Kiniksa (KNSA) and Kite, a Gilead company (GILD), expect to commence a Phase 2 trial evaluating the investigational combination of Yescarta and mavrilimumab in relapsed or refractory large B-cell lymphoma in the second half of 2020. The objective of the trial is to determine the effect of mavrilimumab on the safety of Yescarta. Preclinical evidence shows the potential for interruption of granulocyte macrophage colony stimulating factor signaling to disrupt chimeric antigen receptor T cell-mediated inflammation without disrupting anti-tumor efficacy.

ShowHide Related Items >><<
KNSA Kiniksa
$21.00 /

+1.18 (+5.95%)

04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
12/06/19 Goldman Sachs
Kiniksa assumed to Buy from Neutral at Goldman Sachs
08/14/19 JMP Securities
Kiniksa price target lowered to $35 from $44 at JMP Securities
GILD Gilead
$79.90 /

+0.24 (+0.30%)

04/27/20 RBC Capital
Gilead's China study modestly favorable, but major impact not likely, says RBC
04/27/20 UBS
Gilead downgraded to Neutral from Buy at UBS
04/24/20 Citi
Citi puts 50:50 odds on Gilead's remdesivir being successsful
04/23/20 Piper Sandler
Piper Sandler says no conclusions can be made from leaked Gilead reports

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.